On December 15, 2022, the OLYMVAX Research Institute was completed and started business in Chengdu Tianfu International Bio-town, serving as a powerful engine for vaccine research and development! A group of leaders attended the inauguration ceremony of OLYMVAX Research Institute to witness this important development milestone of OLYMVAX, including Fan Shaowen, Chairman of Chengdu Olymvax Biopharmaceuticals Inc., Fan Fan, President of OLYMVAX Research Institute, Zhao Hui, Deputy Secretary of the Party Committee of Administration for Market Regulation of Sichuan Province, Zeng Ke, Deputy Director of Management Committee of Chengdu High-tech Zone, Nicole Cooper, Deputy Consul General of Australian Consulate General in Chengdu, Zhang Tao, Vice President of Chengdu Medical College, Li Qi, Deputy Director of Biological Industry Bureau of Chengdu High-tech Zone, Xu Hong, Chairman of the Intellectual Property Service Alliance of Chengdu High-tech Zone, and Li Xinwei, Chairman of Chengdu Tianfu International Bio-town Group Co., Ltd.
Located in Building D3 of Chengdu Tianfu International Bio-town, with an area of 6,600 square meters, OLYMVAX Research Institute focuses on the research and development of biological products such as virus vaccines, bacterial vaccines, recombinant protein vaccines, nucleic acid vaccines and new vaccine adjuvants. It is composed of large-scale cell and bacterial culture technology platform, recombinant gene engineering technology platform, protein purification coupling technology platform, quality evaluation system service platform, pilot research technology platform, and new high-end adjuvant and immunosuppressant technology platform.
“OLYMVAX Research Institute, under the dual-track driven R&D mechanism of ‘technology introduction’ and ‘independent R&D’, will focus on three major fields of bacterial vaccines, viral vaccines and nucleic acid vaccines in the future.” At the beginning of the ceremony, Mr. Fan Shaowen, Chairman of OLYMVAX, introduced the development concept of the Institute to all the guests.
Undoubtedly long-term cooperation will actualize long-term development. At the event site, Chengdu XENOMIX Biotechnology Co., Ltd., a subsidiary of OLYMVAX, held a signing ceremony for the capital increment agreement with Chengdu Biological City No. 1 Equity Investment Fund Partnership. This cooperation is a new starting point for coexistence and win-win cooperation. The future journey is full of challenges, but we will uphold the concept of harmonious coexistence, and integrate more advantageous forces and resources with a more open mindset to jointly work out an innovative path for industrial development.
OLYMVAX Research Institute has established a multidisciplinary and interdisciplinary team, and established a close cooperation with all parties in the industry on the basis of the strategy of “going global and bringing in”. At the ceremony, the Institute was granted the title of “Griffith University-Joint Laboratory for Vaccine Development” by Griffith University in Australia, “China National Research Center for Immunological Products - Joint Laboratory” by Army Medical University, “Chengdu Medical College - Biotechnology and Bioengineering Professional Practice Teaching Base” and “Chengdu Medical College - Innovation and Entrepreneurship Practice Base for College Students and Biomedical Project R&D and Transformation Base” by Chengdu Medical College, and “Chengdu High-tech Zone Intellectual Property Service Alliance - Member Unit” by Chengdu High-tech Zone Intellectual Property Service Alliance.
At an auspicious time, Secretary Zhao Hui, Director Zeng Ke, Principal Zhang Tao, Chairman Fan Shaowen, and President Fan Fan jointly cut the ribbon for the opening of the OLYMVAX Research Institute.
After the ceremony, the guests entered the Institute for a visit.
Upholding the innovative and open corporate culture, the Institute will establish multi-dimensional cooperative relationships to jointly promote the development of the vaccine field and provide innovative and effective solutions against significant health issues faced by China and the world.